SBIR-STTR Award

Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
Award last edited on: 2/19/2024

Sponsored Program
STTR
Awarding Agency
NIH : NIAMS
Total Award Amount
$2,431,957
Award Phase
2
Solicitation Topic Code
846
Principal Investigator
Farshid Guilak

Company Information

Cytex Therapeutics Inc

2608 Erwin Road Suite 19a
Durham, NC 27705
   (919) 912-9839
   cestes@cytextherapeutics.com
   www.cytextherapeutics.com

Research Institution

Colorado State University

Phase I

Contract Number: 1R42AR066439-01A1
Start Date: 9/8/2015    Completed: 8/31/2016
Phase I year
2015
Phase I Amount
$190,720
The treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutions. Left untreated, these lesions tend to degenerate to chronic pain and osteoarthritis (OA), ultimately requiring a total joint replacement. For patients suffering from knee OA, and, in particular, unicompartmental OA, unicondylar knee arthroplasty (UKA) is an available first line treatment option that provides many potential advantages over more common total knee replacement procedures. However, this approach remains controversial due to variable clinical results and high rates of revision associated with current implant designs. To overcome the pitfalls associated with current implant designs, we have developed a novel tissue engineering therapy for unicondylar resurfacing for knee OA. The overall goals of this study are two-fold: (Phase I) to repair large osteochondral defects in the knee, for which current treatment paradigms are currently contraindicated, and (Phase II) to resurface a diseased femoral condyle in an ovine model of unicompartmental OA. Our approach for both phases is based on a high-performance three-dimensionally (3D) woven scaffold that mimics the biomechanical properties of native articular cartilage at the initial time of cell seeding, thus providing a highly functional implant. Its unique woven architecture forms to the anatomical curvature of the condyle, provides an environment that encourages cell growth and differentiation, and is capable of integrating with subchondral bone. In Phase I, efficacy of the technology will be evaluated in a large, full-thickness cartilage defect located in the medial condyle of the knee. The following groups will be evaluated: 1) a defect only control group, 2) an acellular scaffold treatment group, 3) autologous mesenchyme derived stem cell (MSC)-seeded scaffold group, and 4) a tissue-engineered treatment group (ex vivo cultured scaffold with autologous MSCs). At 6 months, the regenerative response of all groups will be evaluated histologically and biomechanically. The most successful treatment will then be translated to Phase II where an anatomically condyle-shaped implant will be used to treat OA. All animals in Phase II will be evaluated at 3, 6, and 12 months following repair. Functional measurements will be taken pre- and postoperatively to evaluate joint function and comfort, while sequential radiographs and MRI will be used to assess any morphological changes. Histological and biomechanical properties of the joint tissues collected from the treated joint will be compared to those from the contralateral limb (negative control) to quantify degradative changes. Serum, synovial fluid, and synovium will be analyzed for biomarkers of OA, as well as for adverse inflammatory reactions and to test for wear debris in the joint. This study will primarily provide valuable data on the ability of out technology to treat a range of cartilage pathology, ranging from large cartilaginous defects to unicompartmental OA. Secondarily, the findings of the study will provide insight into clinical, imaging, and serum/synovial fluid biomarkers that may provide additional information on the predictive validity of such measures in knee OA.

Public Health Relevance Statement:


Public Health Relevance:
The aim of this project is to study a biosynthetic implant that can be used for treatment of cartilage pathologies ranging from large defects to unicompartmental knee osteoarthritis while providing significant advantages over typical knee replacement procedures. The basis of this work involves the combination of bone marrow-derived adult stem cells and a novel, high-performance three-dimensionally woven scaffold that is designed to withstand joint loading and induce differentiation of the stem cells. The ultimate goal of this study is to develop tissue-engineering technologies that can eventually be used to treat osteoarthritis and other joint diseases.

Project Terms:
adulthood; adult human (21+); Adult Human; 21+ years old; Adult; Affect; Age; Aging; Animals; Engineering / Architecture; Architecture; biological material; Biomaterials; Biocompatible Materials; biomechanical; Biomechanics; bone; Bone Marrow Reticuloendothelial System; Bone Marrow; Cartilagenous Tissue; Cartilage; cartilage disorder; Cartilage Diseases; articular cartilage; Cell Differentiation; Cell Differentiation process; Cellular Growth; Cellular Expansion; cell growth; Cells; Control Groups; disease/disorder; Disorder; Disease; Environment; Non-Trunk; Limbs; Extremities; Limb structure; Goals; Modern Man; Man (Taxonomy); Human; In Vitro; joint disorder; arthropathy; arthropathic; Joint Diseases; arthropathies; Articulation; Joints; Knee; lifespan; life span; Length of Life; Longevity; Zeugmatography; Nuclear Magnetic Resonance Imaging; NMR Tomography; NMR Imaging; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; Magnetic Resonance Imaging Scan; MRI; MR Tomography; MR Imaging; Magnetic Resonance Imaging; Morbidity; Morbidity - disease rate; Mortality; Mortality Vital Statistics; Orthopedic Surgical Profession; Orthopedic; Orthopedics; hypertrophic arthritis; degenerative joint disease; Osteoarthrosis; Osteoarthritis; Degenerative Arthritis; Degenerative polyarthritis; Painful; Pain; Pathology; Patients; QOL; Quality of life; Risk; Risk Factors; Solutions; Progenitor Cells; Stem cells; Synovia; Synovial Fluid; Synovium; Membrana Synovialis Capsulae Articularis; Synovial Membrane; Technology; Testing; fabric; Textiles; Time; Body Tissues; Tissues; Translating; United States; Work; Measures; Total Knee Replacement; Total Arthroplasty of the Knee; TKR - Total knee replacement; Prosthetic total arthroplasty of the knee; Knee replacement; Knee joint replacement operation; Knee arthroplasty; Arthroplasty, Replacement, Knee; chronic painful condition; chronic pain; Caring; Mesenchymas; Mesenchyme; base; Procedures; joint replacement; Joint Prosthesis Implantation; Replacement Arthroplasty; Left; Medial; Area; Clinical; repair; repaired; Phase; Histologically; Histologic; Lesion; Fiber; Hyaline Cartilage; Blood Serum; Serum; disability; insight; Individual; Measurement; Selection Criteria; Veterinarians; Funding; Shapes; Inflammatory; tool; scaffolding; scaffold; Life; Knee Osteoarthritis; Autologous; Contralateral; Reaction; Source; Health Care Industry; Healthcare Industry; surgery; Surgical Procedure; Surgical Interventions; Surgical; Operative Procedures; Operative Surgical Procedures; engineered tissue; Tissue Engineering; Performance; success; Structure; novel; economic impact; disorder model; Disease model; Modeling; LOINC Axis 2 Property; Property; Biological Mimetics; Biomimetics; epsilon-caprolactone; caprolactone; adult stem cell; Mesenchymal Progenitor Cell; Mesenchymal Stem Cells; Thickness; Thick; Defect; Data; Economic Burden; Harvest; developmental; Development; joint function; point of care; imaging; Image; preclinical trial; pre-clinical trial; pre-clinical study; preclinical study; stem cell differentiation; designing; design; cost-effective; cost effective; osteochondral; osteochondral tissue; Trauma; innovative; innovate; innovation; Implant; public health relevance; FDA approved; effective treatment; effective therapy; biomarker; biologic marker; Biological Markers; Phase I Study; phase 1 study; phase II study; phase 2 study; joint loading

Phase II

Contract Number: 4R42AR066439-02
Start Date: 4/1/2017    Completed: 3/31/2019
Phase II year
2017
(last award dollars: 2023)
Phase II Amount
$2,241,237

The treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutions. Left untreated, these lesions tend to degenerate to chronic pain and osteoarthritis (OA), ultimately requiring a total joint replacement. For patients suffering from knee OA, and, in particular, unicompartmental OA, unicondylar knee arthroplasty (UKA) is an available first line treatment option that provides many potential advantages over more common total knee replacement procedures. However, this approach remains controversial due to variable clinical results and high rates of revision associated with current implant designs. To overcome the pitfalls associated with current implant designs, we have developed a novel tissue engineering therapy for unicondylar resurfacing for knee OA. The overall goals of this study are two-fold: (Phase I) to repair large osteochondral defects in the knee, for which current treatment paradigms are currently contraindicated, and (Phase II) to resurface a diseased femoral condyle in an ovine model of unicompartmental OA. Our approach for both phases is based on a high-performance three-dimensionally (3D) woven scaffold that mimics the biomechanical properties of native articular cartilage at the initial time of cell seeding, thus providing a highly functional implant. Its unique woven architecture forms to the anatomical curvature of the condyle, provides an environment that encourages cell growth and differentiation, and is capable of integrating with subchondral bone. In Phase I, efficacy of the technology will be evaluated in a large, full-thickness cartilage defect located in the medial condyle of the knee. The following groups will be evaluated: 1) a defect only control group, 2) an acellular scaffold treatment group, 3) autologous mesenchyme derived stem cell (MSC)-seeded scaffold group, and 4) a tissue-engineered treatment group (ex vivo cultured scaffold with autologous MSCs). At 6 months, the regenerative response of all groups will be evaluated histologically and biomechanically. The most successful treatment will then be translated to Phase II where an anatomically condyle-shaped implant will be used to treat OA. All animals in Phase II will be evaluated at 3, 6, and 12 months following repair. Functional measurements will be taken pre- and postoperatively to evaluate joint function and comfort, while sequential radiographs and MRI will be used to assess any morphological changes. Histological and biomechanical properties of the joint tissues collected from the treated joint will be compared to those from the contralateral limb (negative control) to quantify degradative changes. Serum, synovial fluid, and synovium will be analyzed for biomarkers of OA, as well as for adverse inflammatory reactions and to test for wear debris in the joint. This study will primarily provide valuable data on the ability of out technology to treat a range of cartilage pathology, ranging from large cartilaginous defects to unicompartmental OA. Secondarily, the findings of the study will provide insight into clinical, imaging, and serum/synovial fluid biomarkers that may provide additional information on the predictive validity of such measures in knee OA.

Public Health Relevance Statement:
The aim of this project is to study a biosynthetic implant that can be used for treatment of cartilage pathologies ranging from large defects to unicompartmental knee osteoarthritis while providing significant advantages over typical knee replacement procedures. The basis of this work involves the combination of bone marrow-derived adult stem cells and a novel, high-performance three-dimensionally woven scaffold that is designed to withstand joint loading and induce differentiation of the stem cells. The ultimate goal of this study is to develop tissue-engineering technologies that can eventually be used to treat osteoarthritis and other joint diseases.

Project Terms:
adulthood; Adult Human; 21+ years old; Adult; Affect; ages; Age; Aging; Anatomy Qualifier; Anatomical Sciences; Anatomic structures; Anatomic Structures and Systems; Anatomic Structure, System, or Substance; Anatomic Sites; Anatomic; Anatomy; Animals; Engineering / Architecture; Architecture; biological material; Biomaterials; Biocompatible Materials; biomechanical; Biomechanics; bone; Bone Marrow Reticuloendothelial System; Bone Marrow; Cartilaginous Tissue; Cartilage; cartilage disorder; Cartilage Diseases; articular cartilage; Cell Differentiation; Cell Differentiation process; Cellular Growth; Cellular Expansion; cell growth; Cell Body; Cells; Control Groups; Disorder; Disease; Environment; Non-Trunk; Limbs; Extremities; Limb structure; Goals; Modern Man; Human; In Vitro; arthropathies; joint disorder; arthropathy; arthropathic; Joint Diseases; Joints; Knee; Longevity; lifespan; life span; Length of Life; Magnetic Resonance Imaging; Zeugmatography; Nuclear Magnetic Resonance Imaging; NMR Tomography; NMR Imaging; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; MRI; MR Tomography; MR Imaging; Morbidity - disease rate; Morbidity; mortality; Orthopedics; Orthopedic Surgical Profession; Orthopedic; Degenerative polyarthritis; osteoarthritic; hypertrophic arthritis; degenerative joint disease; Osteoarthrosis; Osteoarthritis; Degenerative Arthritis; Pain; Painful; Pathology; Patients; Postoperative Period; Postoperative; Post-Operative; Quality of life; QOL; Risk; Risk Factors; Stem cells; Progenitor Cells; Synovial Fluid; Synovia; Synovial Membrane; Synovium; Membrana Synovialis Capsulae Articularis; Technology; Testing; Textiles; fabric; Time; Tissues; Body Tissues; Translating; United States; Work; Measures; total knee arthroplasty; Total Knee Replacement; Knee replacement; Knee joint replacement operation; Knee arthroplasty; knee replacement arthroplasty; chronic painful condition; chronic pain; Mesenchymas; Mesenchyme; base; Procedures; joint replacement; joint arthroplasty; Joint Prosthesis Implantation; Arthroplasty; Replacement Arthroplasty; Left; Medial; Area; Clinical; repair; repaired; Phase; Histologically; Histologic; Lesion; Fiber; Hyaline Cartilage; Blood Serum; Serum; disability; insight; Individual; Measurement; Selection Criteria; Veterinarians; Funding; Morphology; Inflammatory; tool; scaffold; scaffolding; Life; Knee Osteoarthritis; Dimensions; Autologous; Contralateral; Reaction; Source; Healthcare Industry; Health Care Industry; Operative Surgical Procedures; surgery; Surgical Procedure; Surgical Interventions; Surgical; Operative Procedures; Tissue Engineering; engineered tissue; Performance; success; Structure; novel; economic impact; Disease model; disorder model; Modeling; Property; Biomimetics; Biological Mimetics; caprolactone; epsilon-caprolactone; adult stem cell; Mesenchymal Stem Cells; Mesenchymal Progenitor Cell; Thick; Thickness; Defect; Data; Economic Burden; Harvest; developmental; Development; joint function; point of care; imaging; Image; pre-clinical study; preclinical study; stem cell differentiation; designing; design; cost effective; cost-effective; osteochondral tissue; osteochondral; Trauma; innovation; innovative; innovate; Implant; FDA approved; standard of care; effective therapy; effective treatment; Biological Markers; biomarker; biologic marker; bio-markers; risk minimization; phase 1 study; Phase I Study; phase 2 study; phase II study; joint loading; Regenerative response; treatment group; implant design; subchondral bone; clinical imaging; cartilaginous